Other immune checkpoints that are targeted by drugs for clinical use (Dempke et al., 2017), including B7H3 (CD276) and TIM3 (HAVCR2), were also found to be highly expressed in patients with high-HIF1A-expression gliomas. Here, CD276 is linked to glioma.